Medicare Enrolled
Dr. Omar Al Ustwani, MD
Internal Medicine · Vineland, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Al Ustwani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Al Ustwani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Al Ustwani
Dr. Omar Al Ustwani is an internal medicine specialist in Vineland, NJ, with 17 years of NPI registration. Based on federal Medicare data, Dr. Al Ustwani performed 69,258 Medicare services across 1,889 unique beneficiaries.
Between the years covered by Open Payments, Dr. Al Ustwani received a total of $5,489 from 69 pharmaceutical and/or device companies across 328 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Al Ustwani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 0% volume in NJ
$5,489 industry payments
Medicare Practice Summary
Medicare Utilization ↗69,258
Medicare services
Top 0% in NJ for internal medicine
1,889
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,074 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
38,250 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 8,800 | $43 | $65 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
3,900 | $0 | $3 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
3,600 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 3,480 | $18 | $50 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,900 | $6 | $50 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,980 | $6 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,164 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 900 | $1 | $50 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
737 | $8 | $30 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
693 | $73 | $150 |
| Anti-nausea injection (ondansetron/Zofran) | 360 | $0 | $2 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 299 | $3 | $50 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
286 | $14 | $75 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
253 | $116 | $300 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
240 | $12 | $79 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
172 | $109 | $199 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
131 | $25 | $95 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
125 | $25 | $200 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
111 | $2 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
107 | $57 | $150 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
80 | $55 | $200 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
79 | $65 | $149 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
78 | $42 | $76 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
73 | $17 | $100 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
54 | $1 | $13 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
53 | $67 | $152 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
50 | $109 | $258 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
44 | $18 | $95 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
40 | $10 | $25 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
40 | $20 | $75 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
39 | $145 | $373 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
37 | $142 | $300 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
37 | $1 | $10 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
30 | $76 | $200 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
25 | $1 | $10 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
11 | $27 | $100 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.2% high complexity
40.9% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,489
Total received (2018-2024)
Avg $784/year across 7 years
Top 14% in NJ for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
328
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,417 (98.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$72 (1.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,261
2023
$1,432
2022
$1,091
2021
$315
2020
$238
2019
$712
2018
$440
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$157
Novartis Pharmaceuticals Corporation
$148
AstraZeneca Pharmaceuticals LP
$129
E.R. Squibb & Sons, L.L.C.
$85
Adaptive Biotechnologies Corporation
$65
Merck Sharp & Dohme LLC
$54
Daiichi Sankyo Inc.
$38
Kite Pharma, Inc.
$38
ARRAY BIOPHARMA INC
$36
SOBI, INC
$36
Stemline Therapeutics Inc.
$34
Celgene Corporation
$33
BeiGene USA, Inc.
$32
GENZYME CORPORATION
$32
Janssen Biotech, Inc.
$31
ABBVIE INC.
$30
Genentech USA, Inc.
$21
Agios Pharmaceuticals, Inc.
$19
Deciphera Pharmaceuticals Inc.
$18
GlaxoSmithKline, LLC.
$18
Tempus AI, Inc
$18
Gilead Sciences, Inc.
$18
Geron Corporation
$18
Janssen Pharmaceuticals, Inc
$17
Incyte Corporation
$17
TerSera Therapeutics LLC
$17
EMD Serono, Inc.
$16
Eisai Inc.
$16
Astellas Pharma US Inc
$15
PUMA BIOTECHNOLOGY, INC.
$15
Celltrion USA Inc.
$14
Exelixis Inc.
$14
Rigel Pharmaceuticals, Inc.
$13
Top 3 companies account for 34.4% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$449
PFIZER INC.
$396
Genentech USA, Inc.
$364
E.R. Squibb & Sons, L.L.C.
$344
AstraZeneca Pharmaceuticals LP
$281
Merck Sharp & Dohme LLC
$255
Pharmacyclics LLC, An AbbVie Company
$210
Janssen Biotech, Inc.
$189
Exelixis Inc.
$154
Janssen Pharmaceuticals, Inc
$150
Abbott Laboratories
$147
Kite Pharma, Inc.
$132
Celgene Corporation
$124
Seagen Inc.
$122
EMD Serono, Inc.
$117
GENZYME CORPORATION
$116
Astellas Pharma US Inc
$108
Lilly USA, LLC
$98
Eisai Inc.
$94
Incyte Corporation
$91
Gilead Sciences, Inc.
$84
Daiichi Sankyo Inc.
$82
ARRAY BIOPHARMA INC
$67
Adaptive Biotechnologies Corporation
$65
GlaxoSmithKline, LLC.
$63
BeiGene USA, Inc.
$59
ABBVIE INC.
$56
EISAI INC.
$51
Stemline Therapeutics Inc.
$50
Ipsen Biopharmaceuticals, Inc
$48
Takeda Pharmaceuticals U.S.A., Inc.
$47
Amgen Inc.
$47
TerSera Therapeutics LLC
$47
Kyowa Kirin, Inc.
$45
AMAG Pharmaceuticals, Inc.
$42
Bayer Healthcare Pharmaceuticals Inc.
$39
Organon LLC
$39
Bayer HealthCare Pharmaceuticals Inc.
$38
SOBI, INC
$36
Rigel Pharmaceuticals, Inc.
$33
Deciphera Pharmaceuticals Inc.
$31
Regeneron Healthcare Solutions, Inc.
$30
Merck Sharp & Dohme Corporation
$29
Secura Bio, Inc.
$27
Genmab U.S., Inc.
$27
TESARO, Inc.
$22
Pharmacyclics LLC, an AbbVie Company
$21
Octapharma USA, Inc.
$19
Agios Pharmaceuticals, Inc.
$19
Tempus AI, Inc
$18
Geron Corporation
$18
CTI BioPharma Corp.
$17
JAZZ PHARMACEUTICALS INC.
$17
Medtronic USA, Inc.
$16
Mirati Therapeutics, Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$15
Helsinn Therapeutics (U.S.), Inc.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Apellis Pharmaceuticals, Inc.
$15
MorphoSys, US Inc.
$15
Celltrion USA Inc.
$14
AbbVie Inc.
$14
Fresenius Kabi USA, LLC
$13
Acrotech Biopharma LLC
$13
Spectrum Pharmaceuticals Inc.
$13
Advanced Accelerator Applications
$13
Foundation Medicine, Inc.
$12
Prometheus Laboratories Inc.
$12
Clovis Oncology, Inc.
$11
Top 3 companies account for 22.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · AUGTYRO · Alecensa · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · COPIKTRA · Cabometyx · Columvi · DARZALEX · DOPTELET · ELIQUIS · ELITEK · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FERAHEME · FOUNDATIONONE · Fabhalta · Folotyn · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kabiven · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LORBRENA · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NINLARO · Nexavar · Nplate · Nubeqa · ONTRUZANT · OPDIVO · OPDUALAG · OSTEOCOOL RF ABLATION · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Perjeta · Pomalyst · Proleukin · QINLOCK · Quadra Allure MP RF CRT Pacemkr · REBLOZYL · RYTELO · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TEPMETKO · TEVIMBRA · TIVDAK · TUKYSA · Tecentriq · VARUBI · VEGZELMA · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XT CDX · XTANDI · Xermelo · Yescarta · ZEJULA · ZOLADEX · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Internal medicine physicians within 10 mi
329
Per 100K population
215.2
County median income
$64,499
Nearest hospital
INSPIRA MEDICAL CENTER VINELAND
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Al Ustwani is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ), with low-engagement industry engagement in the top 14% of NJ peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Al Ustwani experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Al Ustwani performed 38,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Al Ustwani receive payments from pharmaceutical companies?
Yes. Dr. Al Ustwani received a total of $5,489 from 69 companies across 328 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Al Ustwani's costs compare to other internal medicine physicians in Vineland?
Dr. Al Ustwani's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Al Ustwani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Vineland
Browse internal medicine physicians in Vineland ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in NJ
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in NJ
Which NJ internal medicine physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology